Charite Research Organisation GmbH

Charité Research Organisation advances cancer care by testing innovative therapies for a wide range of solid tumors and hematologic malignancies.

• Advanced melanoma
• Non‑small cell lung cancer
• Colorectal cancer
• Breast cancer (HER2‑positive and HER2‑low)
• High‑grade serous ovarian cancer
• Renal cell carcinoma
• Lymphoma (diffuse large B‑cell, Hodgkin’s, peripheral T‑cell)

The trials aim to evaluate efficacy and safety of targeted agents and immunotherapies, helping to improve treatment outcomes for patients across Berlin and beyond.

Research at Charité focuses on immune‑mediated diseases, exploring new biologics that modulate the immune response.

• Atopic dermatitis
• Plaque psoriasis
• Ulcerative colitis
• Crohn’s disease
• Systemic lupus erythematosus
• Chronic inflammatory demyelinating polyneuropathy

These studies assess whether novel agents can reduce disease activity and improve quality of life for individuals living with chronic inflammation.

The site conducts trials targeting metabolic health, including obesity and diabetes management.

• Type 2 Diabetes Mellitus
• Obesity
• Metabolic syndrome
• Nutritional deficiencies

Objectives include testing agents that promote weight loss, improve glycemic control, and address associated cardiovascular risk factors.

Charité’s program evaluates therapies for cardiopulmonary conditions, aiming to alleviate symptoms and slow disease progression.

• Chronic obstructive pulmonary disease (COPD)
• Mild to moderate asthma
• Hypertension
• Heart failure

The research measures functional improvement, reduction in exacerbations, and overall patient well‑being.

Studies at Charité address serious bacterial infections and sepsis, testing new antimicrobial strategies.

• Clostridioides difficile infection
• Sepsis
• Septic shock

Trials focus on safety and efficacy of novel antibiotics or adjunctive therapies to improve survival and recovery rates.